在大B细胞淋巴瘤中选择最佳的治疗方法和优化测序策略
Gloria Iacoboni1, Franck Morschhauser2
1Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Hematology. American Society of Hematology. Education Program
|December 5, 2025
概括
像CAR T细胞和双特异性抗体这样的T细胞重定向疗法正在改变大B细胞淋巴瘤的结果. 临床试验现在正在研究这些早期的治疗方法,将资格标准从以移植为重点转移到以CAR T细胞为重点.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 在历史上,复发性/耐药性大B细胞淋巴瘤 (LBCL) 的预后一直很差.
- T细胞重定向策略,如仿真抗原受体T细胞 (CAR T) 和双特异性抗体 (bsAbs),代表了显著的进步.
- 由于这些新型免疫疗法,LBCL的治疗模式正在迅速发展.
研究的目的:
- 为了说明LBCL治疗策略的动态转变.
- 从涉及T细胞重定向疗法的临床案例中突出展示关键的学习点.
- 讨论这个不断变化的领域的未来机会和未解决的问题.
主要方法:
- 讨论两个说明性的临床案例.
- 专注于复发/耐药的大B细胞淋巴瘤的患者.
- 分析由T细胞重定向剂驱动的治疗场景变化.
主要成果:
- T细胞重定向策略显著改善了复发性/耐药性LBCL的结果.
- 目前正在进行的试验正在探索CAR T和bsAbs在早期疗法中的使用.
- 目标患者群体的定义正在转向"符合CAR T资格"与传统的"移植资格"标准一起.
结论:
- 治疗LBCL正在进入一个由T细胞重定向疗法定义的新时代.
- 临床案例研究为这些治疗方法的实际应用和挑战提供了宝贵的见解.
- 需要进一步的研究来优化这些疗法的使用,并解决剩余的临床问题.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


